Patient characteristics at allo-HCT (n = 90)
| . | Total (n = 90) . | 5-6/6 HLA-matched related (n = 14) . | Unrelated (n = 26) . | CB (n = 30) . | HLA-haploidentical related (n = 20) . | P . |
|---|---|---|---|---|---|---|
| Age at allo-HCT (y) | .63 | |||||
| Median (range) | 60 (27-70) | 60 (40-69) | 60 (35-67) | 61 (36-70) | 60 (27-67) | |
| Gender | .29 | |||||
| Male | 50 (56) | 6 (43) | 12 (46) | 18 (60) | 14 (70) | |
| Female | 40 (44) | 8 (57) | 14 (54) | 12 (40) | 6 (30) | |
| ATL subtype | .60 | |||||
| Acute type | 65 (72) | 11 (79) | 20 (77) | 22 (73) | 12 (60) | |
| Lymphoma type | 25 (28) | 3 (21) | 6 (23) | 8 (27) | 8 (40) | |
| mATL-PI at diagnosis | .25 | |||||
| Low risk | 30 (33) | 1 (7) | 10 (38) | 11 (37) | 8 (40) | |
| Intermediate risk | 52 (58) | 12 (86) | 14 (54) | 17 (57) | 9 (45) | |
| High risk | 8 (9) | 1 (7) | 2 (8) | 2 (7) | 3 (15) | |
| Induction chemotherapy | .46 | |||||
| mLSG15 regimen | 79 (88) | 13 (93) | 22 (85) | 28 (93) | 16 (80) | |
| CHOP-like regimen | 11 (12) | 1 (7) | 4 (15) | 2 (7) | 4 (20) | |
| Response to induction therapy | .98 | |||||
| CR | 36 (40) | 6 (43) | 9 (35) | 12 (40) | 9 (45) | |
| PR | 34 (38) | 4 (29) | 10 (38) | 12 (40) | 8 (40) | |
| SD | 4 (4) | 1 (7) | 1 (4) | 1 (3) | 1 (5) | |
| PD | 16 (18) | 3 (21) | 6 (23) | 5 (17) | 2 (10) | |
| Number of regimens before allo-HCT | .32 | |||||
| 1 | 69 (77) | 8 (57) | 20 (77) | 25 (83) | 16 (80) | |
| 2 | 20 (22) | 6 (43) | 5 (19) | 5 (17) | 4 (20) | |
| 4 | 1 (1) | 0 | 1 (4) | 0 | 0 | |
| Mogamulizumab use before allo-HCT | 6 (7) | 1 (7) | 3 (12) | 2 (7) | 0 | .52 |
| Number of cycles, median (range) | 3 (1-7) | 6 | 4 (1-7) | 1.5 (1-2) | — | — |
| Interval between the last dose to allo-HCT (days), median (range) | 74 (45-154) | 78 | 70 (49-154) | 67 (45-89) | — | — |
| Interval between the diagnosis and allo-HCT (days), median (range) | 128 (42-471) | 107 (58-278) | 163 (109-382) | 124 (83-282) | 120 (42-471) | <.001 |
| Disease status at allo-HCT | .69 | |||||
| CR | 41 (46) | 6 (43) | 12 (46) | 12 (40) | 11 (55) | |
| PR | 28 (31) | 4 (29) | 11 (42) | 10 (33) | 3 (15) | |
| SD | 6 (7) | 1 (7) | 1 (4) | 2 (7) | 2 (10) | |
| PD | 15 (17) | 3 (21) | 2 (8) | 6 (20) | 4 (20) | |
| Stem cell source | — | |||||
| BM | 27 (30) | 6 (43) | 21 (81) | 0 | 0 | |
| PBSC | 33 (37) | 8 (57) | 5 (19) | 0 | 20 (100) | |
| CB | 30 (33) | 0 | 0 | 30 (100) | 0 | |
| HTLV-1 seropositive donor | 4 (4) | 3 (21) | 0 | 0 | 1 (5) | — |
| Conditioning therapy | <.001 | |||||
| Cy/TBI-based MAC | 7 (8) | 4 (29) | 2 (8) | 1 (3) | 0 | |
| Flu/Bu-based MAC | 7 (8) | 3 (21) | 1 (4) | 1 (3) | 2 (10) | |
| Flu/Mel-based RIC | 58 (64) | 6 (43) | 10 (38) | 26 (87) | 16 (80) | |
| Flu-Bu-based RIC | 16 (18) | 1 (7) | 13 (50) | 0 | 2 (10) | |
| Flu/Bu2/Mel80 | 2 (2) | 0 | 0 | 2 (7) | 0 | |
| GVHD prophylaxis | ||||||
| ATG use | 10 (11) | 2 (14) | 8 (31) | 0 | 0 | — |
| ATG dose (mg/kg), median (range) | 2.0 (1.0-2.5) | 1.8 (1.5-2.0) | 2.0 (1.0-2.5) | — | — | — |
| PTCy use | 19 (21) | 0 | 0 | 0 | 19 (95) | — |
| . | Total (n = 90) . | 5-6/6 HLA-matched related (n = 14) . | Unrelated (n = 26) . | CB (n = 30) . | HLA-haploidentical related (n = 20) . | P . |
|---|---|---|---|---|---|---|
| Age at allo-HCT (y) | .63 | |||||
| Median (range) | 60 (27-70) | 60 (40-69) | 60 (35-67) | 61 (36-70) | 60 (27-67) | |
| Gender | .29 | |||||
| Male | 50 (56) | 6 (43) | 12 (46) | 18 (60) | 14 (70) | |
| Female | 40 (44) | 8 (57) | 14 (54) | 12 (40) | 6 (30) | |
| ATL subtype | .60 | |||||
| Acute type | 65 (72) | 11 (79) | 20 (77) | 22 (73) | 12 (60) | |
| Lymphoma type | 25 (28) | 3 (21) | 6 (23) | 8 (27) | 8 (40) | |
| mATL-PI at diagnosis | .25 | |||||
| Low risk | 30 (33) | 1 (7) | 10 (38) | 11 (37) | 8 (40) | |
| Intermediate risk | 52 (58) | 12 (86) | 14 (54) | 17 (57) | 9 (45) | |
| High risk | 8 (9) | 1 (7) | 2 (8) | 2 (7) | 3 (15) | |
| Induction chemotherapy | .46 | |||||
| mLSG15 regimen | 79 (88) | 13 (93) | 22 (85) | 28 (93) | 16 (80) | |
| CHOP-like regimen | 11 (12) | 1 (7) | 4 (15) | 2 (7) | 4 (20) | |
| Response to induction therapy | .98 | |||||
| CR | 36 (40) | 6 (43) | 9 (35) | 12 (40) | 9 (45) | |
| PR | 34 (38) | 4 (29) | 10 (38) | 12 (40) | 8 (40) | |
| SD | 4 (4) | 1 (7) | 1 (4) | 1 (3) | 1 (5) | |
| PD | 16 (18) | 3 (21) | 6 (23) | 5 (17) | 2 (10) | |
| Number of regimens before allo-HCT | .32 | |||||
| 1 | 69 (77) | 8 (57) | 20 (77) | 25 (83) | 16 (80) | |
| 2 | 20 (22) | 6 (43) | 5 (19) | 5 (17) | 4 (20) | |
| 4 | 1 (1) | 0 | 1 (4) | 0 | 0 | |
| Mogamulizumab use before allo-HCT | 6 (7) | 1 (7) | 3 (12) | 2 (7) | 0 | .52 |
| Number of cycles, median (range) | 3 (1-7) | 6 | 4 (1-7) | 1.5 (1-2) | — | — |
| Interval between the last dose to allo-HCT (days), median (range) | 74 (45-154) | 78 | 70 (49-154) | 67 (45-89) | — | — |
| Interval between the diagnosis and allo-HCT (days), median (range) | 128 (42-471) | 107 (58-278) | 163 (109-382) | 124 (83-282) | 120 (42-471) | <.001 |
| Disease status at allo-HCT | .69 | |||||
| CR | 41 (46) | 6 (43) | 12 (46) | 12 (40) | 11 (55) | |
| PR | 28 (31) | 4 (29) | 11 (42) | 10 (33) | 3 (15) | |
| SD | 6 (7) | 1 (7) | 1 (4) | 2 (7) | 2 (10) | |
| PD | 15 (17) | 3 (21) | 2 (8) | 6 (20) | 4 (20) | |
| Stem cell source | — | |||||
| BM | 27 (30) | 6 (43) | 21 (81) | 0 | 0 | |
| PBSC | 33 (37) | 8 (57) | 5 (19) | 0 | 20 (100) | |
| CB | 30 (33) | 0 | 0 | 30 (100) | 0 | |
| HTLV-1 seropositive donor | 4 (4) | 3 (21) | 0 | 0 | 1 (5) | — |
| Conditioning therapy | <.001 | |||||
| Cy/TBI-based MAC | 7 (8) | 4 (29) | 2 (8) | 1 (3) | 0 | |
| Flu/Bu-based MAC | 7 (8) | 3 (21) | 1 (4) | 1 (3) | 2 (10) | |
| Flu/Mel-based RIC | 58 (64) | 6 (43) | 10 (38) | 26 (87) | 16 (80) | |
| Flu-Bu-based RIC | 16 (18) | 1 (7) | 13 (50) | 0 | 2 (10) | |
| Flu/Bu2/Mel80 | 2 (2) | 0 | 0 | 2 (7) | 0 | |
| GVHD prophylaxis | ||||||
| ATG use | 10 (11) | 2 (14) | 8 (31) | 0 | 0 | — |
| ATG dose (mg/kg), median (range) | 2.0 (1.0-2.5) | 1.8 (1.5-2.0) | 2.0 (1.0-2.5) | — | — | — |
| PTCy use | 19 (21) | 0 | 0 | 0 | 19 (95) | — |
Patient characteristics were compared among the 4 groups according to donor type.
ATG, anti-thymocyte globulin; BM, bone marrow; CB, cord blood; Cy, cyclophosphamide; PBSC, peripheral blood stem cell; TBI, total body irradiation.